Author Contributions: Dr Lenze had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Lenze, Rollman, Shear, Dew, Pollock, Butters, Reynolds.
Acquisition of data: Lenze, Rollman, Shear, Dew, Ciliberti, Costantino, Snyder.
Analysis and interpretation of data: Lenze, Rollman, Shear, Dew, Pollock, Shi, Spitznagel, Andreescu, Butters, Reynolds.
Drafting of the manuscript: Lenze, Shear, Dew, Reynolds.
Critical revision of the manuscript for important intellectual content: Lenze, Rollman, Shear, Dew, Pollock, Ciliberti, Costantino, Snyder, Shi, Spitznagel, Andreescu, Butters, Reynolds.
Statistical analysis: Dew, Shi, Spitznagel, Butters.
Obtained funding: Lenze, Shear, Reynolds.
Administrative, technical, or material support: Lenze, Rollman, Pollock, Ciliberti, Costantino, Reynolds.
Study supervision: Lenze, Rollman, Shear, Dew, Pollock, Andreescu, Reynolds.
Financial Disclosure: Dr Lenze reported being a consultant for Fox Learning Systems; being a consultant for the Veteran's Medical Research Foundation from 2007-2008; receiving research support from Forest Laboratories (current), Pfizer, Novartis, and OrthoMcNeill Neurologics (until 2007); and receiving an honorarium from Eli Lilly for a talk in 2005. Dr Rollman reported serving on a primary care consultant panel for Wyeth in 2004. Dr Shear reported receiving investigator-initiated research support from Forest (until 2005), being a consultant for Forest (until 2007), and being on an advisory board for Pfizer (until 2006). Dr Pollock reported serving on the advisory board of Forest Laboratories and being a faculty member of the Lundbeck International Institute; currently being a consultant for Lundbeck and Wyeth; serving as a consultant for Takeda in 2007; and before 2004, participating in speakers bureaus for Forest and Sepracor pharmaceuticals. Dr Reynolds reported receiving research support (drug only) from Forest, GlaxoSmithKline, Pfizer, Bristol-Myers Squibb, Wyeth, and Eli Lilly. No other authors reported any financial disclosures.
Funding/Support: This work was supported by grants R01 MH070547 from the National Institutes of Health, P30 MH068579 from the Center for Mental Health Services Research (Enola Proctor, PhD, principal investigator), and P30 MH71944 from the Advanced Center for Interventions and Services Research in Late-Life Mood Disorders (Dr Reynolds, principal investigator); the John A. Hartford Center of Excellence in Geriatric Psychiatry (Dr Reynolds, principal investigator); and the University of Pittsburgh Medical Center endowment in geriatric psychiatry (Dr Reynolds). Forest Laboratories Inc, which holds the US patent for escitalopram, provided escitalopram and matching placebo for the study.
Role of the Sponsors: Neither the National Institutes of Health nor Forest Laboratories Inc had a role in the design and conduct of the study, in the collection, management, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.
Additional Contributions: We thank the patients for their participation. Kris Koenig, MBA (employee of University of Pittsburgh), provided management of the study and Linda Ball, PhD (employee of Department of Psychiatry, Washington University), provided critical review of the manuscript. Neither received any additional compensation outside of their paid position.